TAS0728|cas:2088323-16-2|西域试剂

TAS0728,99.15%

产品编号：Bellancom-111553| CAS NO：2088323-16-2| 分子式：C₂₆H₃₂N₈O₃| 分子量：504.58

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-111553	￥2800.00	杭州北京（现货）
Bellancom-111553	￥4500.00	杭州北京（现货）
Bellancom-111553	￥13500.00	杭州北京（现货）
Bellancom-111553	￥21500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

TAS0728

产品介绍

TAS0728 是一种有效的、选择性的、口服活性的、不可逆的共价结合 HER2 抑制剂，其 IC₅₀ 为13 nM。TAS0728 对于 BMX、HER4、BLK、EGFR、JAK3、SLK 和LOK 也存在抑制效果，其 IC₅₀ 值分别为 4.9、8.5、31、65、33、25 和 86 nM。此外，TAS0728 对 HER2、HER3 和下游效应蛋白的磷酸化还表现出强大而持久的抑制作用。

生物活性

TAS0728 is a potent, selective, orally active, irreversible and covalent-binding HER2 inhibitor, with an IC₅₀ of 13 nM. TAS0728 also shows IC₅₀s of 4.9, 8.5, 31, 65, 33, 25 and 86 nM for BMX、HER4、BLK、EGFR、JAK3、SLK and LOK respectively. Furthermore, TAS0728 exhibits robust and sustained inhibition of the phosphorylation of HER2HER3, and downstream effectors.

体外研究

TAS0728 is a covalent-binding inhibitor of HER2 kinase and exhibits high selectivity for HER2 kinase. It also shows inhibitory activity against BMX, HER4, BLK, EGFR, JAK3, SLK, and LOK.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay

Cell Line:	HER2-amplified SK-BR-3/AU565/BT-474/NCI-N87/Calu-3 cells
Concentration:
Incubation Time:
Result:	The GI₅₀ values of TAS0728 were 5.0/5.1/3.6/1.6/6.9 nM relatively for HER2-amplified SK-BR-3/AU565/BT-474/NCI-N87/Calu-3 cells. Inhibited the in vitro proliferation of five HER2-amplified cell lines. Showed potent inhibitory activities against cancer cell lines with HER2 amplification.

Western Blot Analysis

Cell Line:	SK-BR-3 cells
Concentration:	30-300 nM
Incubation Time:	3 and 48 hours
Result:	Showed sustained inhibition of HER2, HER3, AKT and ERK phosphorylation.

体内研究
(In Vivo)

TAS0728 reveals the sustained and targeted inhibition of phosphorylation of HER2, HER3, AKT and ERK. TAS0728 also shows the ability of tumor regression and low toxicity.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male nude mice
Dosage:	7.5, 15, 30 and 60 mg/kg
Administration:	Oral gavage; 7.5, 15, 30 and 60 mg/kg a day;14 days
Result:	Rapidly eliminated within 24 hours.

Animal Model:	Mice bearing NCI-N87 xenografts
Dosage:	60 mg/kg
Administration:	Oral gavage; 60 mg/kg a day; 14 days
Result:	Revealed sustained target inhibition of HER2, HER3, AKT and ERK.

Animal Model:	Mice with NCI-N87 HER2–amplified human gastric cancer
Dosage:	7.5, 15, 30 and 60 mg/kg
Administration:	Oral gavage; 7.5, 15, 30 and 60 mg/kg a day; 14 days
Result:	Well tolerated in all mice. Significant tumor regression was observed in mice treated with 60 mg/kg/day.

Animal Model:	NCI-N87 peritoneal dissemination model
Dosage:	30 and 60 mg/kg
Administration:	Oral gavage; 30and 60 mg/kg a day; 120 days
Result:	No evident toxicity, including diarrhea and body weight loss in the long-term dosing of TAS0728.

体内研究

TAS0728 reveals the sustained and targeted inhibition of phosphorylation of HER2, HER3, AKT and ERK. TAS0728 also shows the ability of tumor regression and low toxicity.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male nude mice
Dosage:	7.5, 15, 30 and 60 mg/kg
Administration:	Oral gavage; 7.5, 15, 30 and 60 mg/kg a day;14 days
Result:	Rapidly eliminated within 24 hours.

Animal Model:	Mice bearing NCI-N87 xenografts
Dosage:	60 mg/kg
Administration:	Oral gavage; 60 mg/kg a day; 14 days
Result:	Revealed sustained target inhibition of HER2, HER3, AKT and ERK.

Animal Model:	Mice with NCI-N87 HER2–amplified human gastric cancer
Dosage:	7.5, 15, 30 and 60 mg/kg
Administration:	Oral gavage; 7.5, 15, 30 and 60 mg/kg a day; 14 days
Result:	Well tolerated in all mice. Significant tumor regression was observed in mice treated with 60 mg/kg/day.

Animal Model:	NCI-N87 peritoneal dissemination model
Dosage:	30 and 60 mg/kg
Administration:	Oral gavage; 30and 60 mg/kg a day; 120 days
Result:	No evident toxicity, including diarrhea and body weight loss in the long-term dosing of TAS0728.

体内研究

TAS0728 reveals the sustained and targeted inhibition of phosphorylation of HER2, HER3, AKT and ERK. TAS0728 also shows the ability of tumor regression and low toxicity.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male nude mice
Dosage:	7.5, 15, 30 and 60 mg/kg
Administration:	Oral gavage; 7.5, 15, 30 and 60 mg/kg a day;14 days
Result:	Rapidly eliminated within 24 hours.

Animal Model:	Mice bearing NCI-N87 xenografts
Dosage:	60 mg/kg
Administration:	Oral gavage; 60 mg/kg a day; 14 days
Result:	Revealed sustained target inhibition of HER2, HER3, AKT and ERK.

Animal Model:	Mice with NCI-N87 HER2–amplified human gastric cancer
Dosage:	7.5, 15, 30 and 60 mg/kg
Administration:	Oral gavage; 7.5, 15, 30 and 60 mg/kg a day; 14 days
Result:	Well tolerated in all mice. Significant tumor regression was observed in mice treated with 60 mg/kg/day.

Animal Model:	NCI-N87 peritoneal dissemination model
Dosage:	30 and 60 mg/kg
Administration:	Oral gavage; 30and 60 mg/kg a day; 120 days
Result:	No evident toxicity, including diarrhea and body weight loss in the long-term dosing of TAS0728.

性状

Solid

溶解性数据

In Vitro:

DMSO : 125 mg/mL (247.73 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.9818 mL	9.9092 mL	19.8185 mL
5 mM	0.3964 mL	1.9818 mL	3.9637 mL
10 mM	0.1982 mL	0.9909 mL	1.9818 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (4.12 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.12 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (4.12 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.12 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (4.12 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.12 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。